ここから本文です
投稿一覧に戻る

メディシンバ応援の掲示板

>>13443

12月の発表

Discussion and conclusions: There was no significant
reduction in motor cortical glial activation following 12–24
weeks of Ibudilast treatment in ALS, as measured by PBR-
PET SUVR. Final clinical trial results including clinical and
biofluid biomarker results will be available at the time of
final presentation during MND Symposium 2019.